ArticleRenal failure2018
Low-dose IL-2 expands CD4
Article in Renal failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The role of Bacillus Calmette-Guérin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2023Pooled it
- Renal single-nucleus transcriptomic of a new model of cardiovascular-kidney-metabolic syndrome in aging swine.American journal of physiology. Renal physiology · 2026Article
- Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.Molecular therapy. Advances · 2026Article
- A human PBMC-based new approach method reveals PFAS-driven T-cell proliferation and immune dysregulation.Archives of toxicology · 2026Article
- Low-Dose Interleukin-2 Enhances Activated Suppressor Regulatory T Cells and CTLA-4 and HLA-DR Expression in Chronic Chikungunya Arthritis.Pathogens (Basel, Switzerland) · 2026Article
- CAR Treg therapies for neurodegenerative diseases.iScience · 2026Review
- Genetically predicted blood metabolites mediate the association between immune cell characteristics and urolithiasis: A Mendelian randomization study and mediation analysis.Genes & diseases · 2025Article
- Adipose Tissue-Derived Mesenchymal Stem Cells Regulate Th17/Treg Cells in a Rat Model of Allergic Rhinitis by Activating IL-2/JAK-3/STAT-5 Signaling Pathway.International archives of allergy and immunology · 2025Article
- Infectious Disease as a Modifiable Risk Factor for Dementia: A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Can immunization with BCG delay the onset of Alzheimer's disease?Geriatrics & gerontology international · 2023Article
- Role of the adaptive immune system in diabetic kidney disease.Journal of diabetes investigation · 2022Review
- Induction of Foxp3 and activation of Tregs by HSP gp96 for treatment of autoimmune diseases.iScience · 2021Article
- Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis.Rheumatology and therapy · 2021Article
- Regulatory T Cells-Related Genes Are under DNA Methylation Influence.International journal of molecular sciences · 2021Review
- Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.Vaccines · 2021Article
- TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases.Frontiers in medicine · 2021Review
- Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy.Clinical nephrology · 2021Article
- Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy.Journal of leukocyte biology · 2020Review
- CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL‑2 and TGF‑β by CD4+ T cells via the STAT5 signaling pathway.Molecular medicine reports · 2020Article
- Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease (CKD) often have CD4+ regulatory T cells (Tregs) dysfunction and chronic inflammation. We aim to investigate the effect, function, and related mechanism of low-dose IL-2 on CD4
methodsA total of 148 newly diagnosed patients with CKD at Stage III and 35 healthy volunteer subjects were recruited into our studies. The number of peripheral Tregs in peripheral blood mononuclear cells isolated from CKD patients, which were characterized by FACS as CD4
resultsWe found that the frequency of peripheral Tregs from CKD patients was significantly lower than that in healthy volunteer subjects. We also showed that IL-2 selectively expanded CD4
conclusionsOur findings support the clinical Treg defects in CKD patients with glomerular diseases, and the rationale of evaluating low-dose IL-2 treatment for selectively modulating CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.